Erectile dysfunction.
In the past 30 years, advances in basic science have been instrumental in the evolution of the male sexual health treatment paradigm from a psychosexual model to a new model, which includes oral and intracavernosal injection pharmacotherapy, vacuum constriction devices and penile prostheses for the treatment of erectile dysfunction. This progress has coincided with an increased understanding of the nature of male sexual health problems, and epidemiological data that confirm that these problems are widely prevalent and the source of considerable morbidity, both for individuals and within relationships.
Australian Centre for Sexual Health, Sydney, New South Wales, Australia.
C G
CG
McMahon
D015897:Comorbidity; D003327:Coronary Disease / Q000453:epidemiology; D004700:Endocrine System Diseases / Q000150:complications; D004730:Endothelium, Vascular / Q000503:physiopathology; D007172:Erectile Dysfunction / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications; D009422:Nervous System Diseases / Q000150:complications; D019935:Penile Implantation; D010413:Penis / Q000098:blood supply; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011613:Psychotherapy; D012306:Risk; D014618:Vacuum; D014652:Vascular Diseases / Q000150:complications; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D058986:Phosphodiesterase 5 Inhibitors; D014665:Vasodilator Agents
alprostadil; erectile dysfunction; intrapenile prosthesis; phosphodiesterase type 5 inhibitor; vacuum constriction device